locally advanced cervical cancer. Malignant neoplasm of cervix uteri
Conditions
Interventions
Intervention Group: The study has a single group. Pretreatment evaluation includes examination, pelvic magnetic resonance imaging, abdominal sonography, and chest x-ray. Patients receive three one-wee
Treatment - Drugs
Sponsors
Vice-chancellery for Research of Mashhad University of Medicla Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Definitive pathologic diagnosis of squamous cell carcinoma; stages IB2, IIA2, and IIB based on the International Federation of Gynecology and Obstetrics classification; age between 18 and 70 years; World Health Organization performance of grade 2 or lower; adequate renal and hepatic function and bone marrow reserve (i.e., absolute granulocyte count equal to or above 2×103 per liter, platelet count equal to or above 100×103 per liter; hemoglobin equal to or above 8.0 grams per deciliter, and glomerular filtration rate equal to or above 50); feasibility of follow-up in the ordered time; and informed consent. Exclusion criteria: history of injection of chemotherapy drug in four weeks before study; serious comorbidities, for example, cardiac disease, poorly controlled diabetes mellitus, malignant hypertension, or bleeding tendency; overt infection; multiple concurrent active cancers; neuropathy grade 2 or greater; pregnancy; and history of serious hypersensitivity or allergy to cisplatin and paclitaxel.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Edema. Timepoint: after each course of chemotherapy. Method of measurement: Clinical examination.;Clinical response of tumor to treatment. Timepoint: At the first presentation, after each cycle of chemotherapy, and after surgery. Method of measurement: Physical examination and pathology.;Overall survival. Timepoint: On year after initiation of treatment. Method of measurement: Physical examination.;Nausea. Timepoint: after each course of chemotherapy. Method of measurement: Physical examination.;Vomit. Timepoint: after each course of chemotherapy. Method of measurement: Physical examination.;Neutropenia. Timepoint: after each course of chemotherapy. Method of measurement: complete blood count.;Neuropathy. Timepoint: after each course of chemotherapy. Method of measurement: Clinical examination. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Elahe Aghel
Mashhad University of Medical Sciences
Outcome results
None listed